Get the Stockscreener App
0.829
0.58%
-0.00485
Longeveron Inc stock is traded at $0.829, with a volume of 267.58K.
It is down -0.58% in the last 24 hours and up +5.16% over the past month.
Longeveron Inc is a clinical-stage biotechnology company developing regenerative medicines to address unmet medical needs for specific aging-related and life-threatening conditions. Its investigational product is Lomecel-B an stem cell formulation sourced from the bone marrow of young, healthy adult donors and has potential mechanisms of action that can promote tissue repair and healing. The company currently has three pipeline indications: Hypoplastic Left Heart Syndrome (HLHS), Alzheimer's disease (AD) and Aging-related Frailty.
See More
Previous Close:
$0.8338
Open:
$0.85
24h Volume:
267.58K
Relative Volume:
0.30
Market Cap:
$16.23M
Revenue:
$1.89M
Net Income/Loss:
$-17.92M
P/E Ratio:
-0.1239
EPS:
-6.69
Net Cash Flow:
$-15.62M
1W Performance:
-9.60%
1M Performance:
+5.16%
6M Performance:
-46.86%
1Y Performance:
-59.16%
1-Day Range:
$0.82
$0.8506
1-Week Range:
$0.811
$0.9302
52-Week Range:
$0.633
$2.31
Longeveron Inc Stock (LGVN) Company Profile
Name
Longeveron Inc
Sector
Industry
Phone
305-302-7158
Address
1951 NW 7TH AVENUE, MIAMI
Compare LGVN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LGVN
Longeveron Inc
|
0.829 | 17.56M | 1.89M | -17.92M | -15.62M | -6.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.08 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
641.99 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.26 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.85 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
183.78 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Longeveron Inc Stock (LGVN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-06-24 | Initiated | ROTH MKM | Buy |
Longeveron Inc Stock (LGVN) Latest News
Is Longeveron Inc. stock in correction or buying zoneJuly 2025 Catalysts & Free High Accuracy Swing Entry Alerts - newser.com
Earnings To Watch: Longeveron Inc (LGVN) Reports Q3 2025 Result - GuruFocus
Is it too late to sell Longeveron Inc.July 2025 Outlook & Daily Growth Stock Investment Tips - newser.com
Will Longeveron Inc. stock remain a Wall Street favoriteWeekly Stock Summary & Consistent Income Trade Recommendations - newser.com
Why analysts upgrade Longeveron Inc. stockDay Trade & Weekly Top Stock Performers List - newser.com
What dividend safety score for Longeveron Inc. stockJuly 2025 News Drivers & AI Forecast Swing Trade Picks - newser.com
Visualizing Longeveron Inc. stock with heatmapsQuarterly Profit Report & Capital Efficiency Focused Strategies - newser.com
Can you recover from losses in Longeveron Inc.July 2025 Weekly Recap & Free Safe Entry Trade Signal Reports - newser.com
How to recover losses in Longeveron Inc. stockCEO Change & Long-Term Capital Growth Strategies - newser.com
What analysts say about Longeveron Inc stockBullish Engulfing Patterns & Free Dashboard to Track Market Momentum - earlytimes.in
Will Longeveron Inc. stock continue dividend increasesWeekly Trade Analysis & Low Drawdown Momentum Ideas - newser.com
What data driven models say about Longeveron Inc.’s futureRisk Management & Fast Moving Market Watchlists - newser.com
Longeveron® to Report Third Quarter 2025 Financial Results and Host Conference Call on November 4, 2025 - The Manila Times
Should you wait for a breakout in Longeveron Inc.Market Rally & Smart Investment Allocation Tips - newser.com
Will Longeveron Inc. stock deliver strong dividend growth2025 Breakouts & Breakdowns & Consistent Growth Equity Picks - Fundação Cultural do Pará
Longeveron® Co-Founder and Chief Science Officer Dr. Joshua Hare Interviewed on NPR’s BioTech Nation Discussing Potential Breakthrough Stem Cell Therapy for Hypoplastic Left Heart Syndrome (HLHS), a Rare Pediatric Congenital Heart Defect - The Manila Times
Longeveron (NASDAQ: LGVN) completes ELPIS II enrollment; HLHS trial top-line Q3 2026 - Stock Titan
Is Longeveron Inc a good long term investmentCapital Gains Strategies & Small Capital Trading Plans - earlytimes.in
Longeveron Inc Stock (LGVN) Financials Data
Revenue
Net Income
Cash Flow
EPS
Longeveron Inc Stock (LGVN) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Soffer Rock | Director |
May 29 '25 |
Sale |
1.30 |
10,000 |
13,000 |
220,034 |
0.27%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):